Recently, immunotherapies, particularly immune-checkpoint blockade (ICB) with anti-PD1/PD-L1 and anti-CTLA4, have revolutionized cancer management, offering encouraging survival benefits superior to targeted treatment in a subset of HCCs[6,7]. This evidence concerns the gene CD274 and cancer.